Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/chemistry , DNA-Binding Proteins/analysis , Endonucleases/analysis , Lung Neoplasms/chemistry , Time Factors , Immunohistochemistry , Cisplatin/therapeutic use , Treatment Outcome , Paclitaxel/therapeutic use , Lung Neoplasms/mortality , Lung Neoplasms/drug therapy , Antineoplastic Agents/therapeutic useABSTRACT
OBJECTIVES: Advancements in non-small cell lung cancer treatment based on targeted therapies have made the differentiation between adenocarcinoma and squamous cell carcinoma increasingly important. Pathologists are challenged to make the correct diagnosis in small specimens. We studied the accuracy of an immunohistochemical panel in subclassifying non-small cell lung cancer in routine small biopsies and compared the results with the diagnosis from resected lung specimens, autopsy samples or biopsied/resected metastases. METHODS: In total, 340 lung cancer biopsies were investigated for the expression of CK5, TTF1, p63 and surfactant. RESULTS: We characterized 166 adenocarcinomas and 124 squamous cell carcinomas. Overall, 85% of cases displayed binary staining (TTF1 positive/p63 negative, and vice versa). The diagnoses of ten cases with a morphology that indicated a specific tumor subtype were changed after immunohistochemistry (IHC). A second specimen was available for 71 patients, and the first diagnosis at biopsy was confirmed in 95% of these cases. Most non-small cell lung cancer cases present a binary immunohistochemical profile in small biopsies, contributing to good diagnostic accuracy with routine markers. In a small proportion of cases, the diagnosis can be changed after IHC even when the morphological aspects indicate one specific tumor subtype. CONCLUSIONS: We recommend that routine small biopsies of lung cancer without classic morphology should be subjected to a minimum immunohistochemical panel to differentiate adenocarcinoma from squamous cell carcinoma.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Carcinoma, Squamous Cell/pathology , Adenocarcinoma/pathology , Biomarkers, Tumor/analysis , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/pathology , Biopsy , Immunohistochemistry , Carcinoma, Squamous Cell/chemistry , Adenocarcinoma/chemistry , Retrospective Studies , Diagnosis, Differential , Lung Neoplasms/chemistryABSTRACT
Cofilin-1 (CFL1), a small protein of 18 kDa, has been studied as a biomarker due to its involvement in tumor cell migration and invasion. Our aim was to evaluate CFL1 as an indicator of malignancy and aggressiveness in sputum samples. CFL1 was analyzed by ELISA immunoassay in the sputum of 73 lung cancer patients, 13 cancer-free patients, and 6 healthy volunteers. Statistical analyses included ANOVA, ROC curves, Spearman correlation, and logistic regression. Sputum CFL1 levels were increased in cancer patients compared to cancer-free patients and volunteers (P<0.05). High expression of sputum CFL1 was correlated to T4 stage (P=0.01) and N stage (P=0.03), tobacco history (P=0.01), and squamous cell carcinoma histologic type (P=0.04). The accuracy of sputum CFL1 in discriminating cancer patients from cancer-free patients and healthy volunteers were 0.78 and 0.69, respectively. CFL1 at a cut-off value of 415.25 pg/mL showed sensitivity/specificity of 0.80/0.70 in differentiating between healthy volunteers and cancer patients. Sputum CFL1 was also able to identify cancer-free patients from patients with lung cancer. The AUC was 0.70 and, at a cut-off point ≥662.63 pg/mL, we obtained 60% sensitivity and 54% specificity. Logistic regression analysis controlled for tobacco history, histologic types, and N stage showed that cancer cell-associated CFL1 was an independent predictor of death. Smoker patients with squamous cell carcinoma, lymph node metastasis and sputum CFL1>1.475 pg/mL showed augmented chance of death, suggesting lung cancer aggressiveness. CFL1 presented diagnostic value in detecting lung cancer and was associated to tumor aggressiveness.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Sputum/chemistry , Carcinoma, Squamous Cell/chemistry , Biomarkers, Tumor/analysis , Cofilin 1/analysis , Lung Neoplasms/chemistry , Prognosis , Enzyme-Linked Immunosorbent Assay , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Case-Control Studies , ROC Curve , Sensitivity and Specificity , Cell Proliferation , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Neoplasm Invasiveness , Neoplasm StagingABSTRACT
Hyaluronan (HA) shows promise for detecting cancerous change in pleural effusion and urine. However, there is uncertainty about the localization of HA in tumor tissue and its relationship with different histological types and other components of the extracellular matrix, such as angiogenesis. We evaluated the association between HA and degree of malignancy through expression in lung tumor tissue and sputum. Tumoral tissue had significantly increased HA compared to normal tissue. Strong HA staining intensity associated with cancer cells was significant in squamous cell carcinoma compared to adenocarcinoma and large cell carcinoma. A significant direct association was found between tumors with a high percentage of HA and MVD (microvessel density) in tumoral stroma. Similarly significant was the direct association between N1 tumors and high levels of HA in cancer cells. Cox multivariate analysis showed significant association between better survival and low HA. HA increased in sputum from lung cancer patients compared to cancer-free and healthy volunteers and a significant correlation was found between HA in sputum and HA in cancer tissue. Localization of HA in tumor tissue was related to malignancy and reflected in sputum, making this an emerging factor for an important diagnostic procedure in patients suspected to have lung cancer. Further study in additional patients in a randomized prospective trial is required to finalize these results and to validate our quantitative assessment of HA, as well as to couple it to gold standard sputum cytology.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Carcinoma/chemistry , Hyaluronic Acid/analysis , Lung Neoplasms/chemistry , Sputum/chemistry , Biopsy , Biomarkers, Tumor/analysis , Case-Control Studies , Carcinoma/pathology , Enzyme-Linked Immunosorbent Assay , Immunohistochemistry , Lung Neoplasms/pathology , Lung/chemistry , Lung/pathology , Neoplasm Staging , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Statistics, Nonparametric , Smoking/adverse effects , Stromal Cells/chemistry , Stromal Cells/pathologyABSTRACT
No abstract available.
Subject(s)
Humans , Male , Middle Aged , Biomarkers, Tumor/analysis , Biopsy , Carcinosarcoma/chemistry , Chemoradiotherapy, Adjuvant , Fatal Outcome , Immunohistochemistry , Lung Neoplasms/chemistry , Mouth Floor/chemistry , Mouth Neoplasms/chemistry , Pneumonectomy , Time Factors , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
No abstract available.
Subject(s)
Aged , Female , Humans , Biomarkers, Tumor/analysis , Biopsy, Large-Core Needle , Bone Neoplasms/chemistry , Immunohistochemistry , Lung Neoplasms/chemistry , Pneumonectomy , Positron-Emission Tomography , Pulmonary Sclerosing Hemangioma/chemistry , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
No abstract available.
Subject(s)
Adult , Humans , Male , Adenocarcinoma/chemistry , Antineoplastic Agents/therapeutic use , Biopsy , Carcinoma, Large Cell/chemistry , Carcinoma, Neuroendocrine/chemistry , Carcinoma, Non-Small-Cell Lung/chemistry , Drug Resistance, Neoplasm , Lung Neoplasms/chemistry , Magnetic Resonance Imaging , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Tomography, X-Ray Computed , Treatment Outcome , Biomarkers, Tumor/analysisABSTRACT
OBJECTIVES: The aim of this study was to compare the expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in small cell lung cancer and subtypes of non-small cell lung cancer and examine their relationships with clinicopathologic factors, response to treatment and survival. METHODS: We examined samples obtained by bronchial endoscopic biopsy from 55 patients with inoperable lung cancer (16 with adenocarcinoma, 17 with squamous cell carcinoma, and 22 with small cell lung cancer). Hypoxiainducible factor 1α and vascular endothelial growth factor were detected using immunohistochemistry. The diagnosis, treatment, and follow-up of patients were conducted according to the standard practice. RESULTS: A significant difference (p=0.022) in hypoxia-inducible factor 1α expression was observed between nonsmall cell lung cancer (75.8% positive) and small cell lung cancer (45.5% positive). The frequency of hypoxiainducible factor 1α nuclear expression was 88.2% in squamous cell carcinoma, 62.5% in adenocarcinoma, and 45.5% in small cell lung cancer. A significant correlation was observed between hypoxia-inducible factor 1α and vascular endothelial growth factor expression (Fisher's exact test, p=0.001) when all types of lung cancer were examined, either collectively or separately. CONCLUSIONS: The expression of hypoxia-inducible factor-1α differs significantly between subtypes of lung cancer. These findings could help elucidate the biology of the different types of non-operable lung carcinomas and have implications for the design of new therapeutic approaches for lung cancer.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Carcinoma, Non-Small-Cell Lung/chemistry , Hypoxia-Inducible Factor 1, alpha Subunit/analysis , Lung Neoplasms/chemistry , Small Cell Lung Carcinoma/chemistry , Biomarkers, Tumor/analysis , Vascular Endothelial Growth Factor A/analysis , Carcinoma, Non-Small-Cell Lung/pathology , Linear Models , Lung Neoplasms/pathology , Neoplasm Staging , Statistics, Nonparametric , Small Cell Lung Carcinoma/pathologyABSTRACT
Cutaneous metastases originating from an internal cancer are relatively uncommon in clinical practice, and metastatic lesions to the breast are rarer than those to the skin. Skin metastases of lung cancer, which may be the first sign of the disease, usually indicate progressive disease and a poor prognosis. We describe a 47-year-old male who presented with recurring masses in the lumbar region bilaterally and the right breast. Immunohistochemical findings and radiological imaging suggested lung cancer. This is the first reported case of small cell lung cancer metastasizing to two separate, uncommon sites, the skin and breast.
Subject(s)
Humans , Male , Middle Aged , Biopsy , Breast Neoplasms, Male/chemistry , Fatal Outcome , Immunohistochemistry , Lung Neoplasms/chemistry , Skin Neoplasms/chemistry , Small Cell Lung Carcinoma/chemistry , Tomography, X-Ray Computed , Treatment Outcome , Biomarkers, Tumor/analysisABSTRACT
En México, la mortalidad debido a enfermedades bronco-respiratorias se ubica en el sexto lugar según datos estadísticos dados por el Instituto Nacional de Enfermedades Respiratorias (INER). Esto genera la necesidad de incrementar la eficiencia en la aplicación de los tratamientos usados para este tipo de patología. Algunos de los métodos utilizados con mayor frecuencia para el tratamiento de estas dolencias hacen uso de micro dispositivos, también conocidos como válvulas endobronquiales. Este es un sistema alternativo que evita cirugías invasivas y logra prolongar e incrementar la calidad de vida de los pacientes. En este trabajo se presenta el análisis del desempeño de la válvula IBV®. Para el desarrollo del estudio numérico se determinaron las dimensiones y propiedades mecánicas del modelo a partir de catálogos del fabricante. Se desarrolló un modelo para el cual se consideraron las propiedades del Nitinol® y Silastic®. Asimismo, se propusieron dos condiciones de operación para la válvula, una anclada en el bronquio y la otra en la condición en la que se encuentra plegada dentro del broncoscopio. Se utilizó el Método del elemento finito (MEF) para simular las condiciones de trabajo de la válvula. Los resultados encontrados muestran el funcionamiento estructural y el nivel de los esfuerzos generados en el implante durante el ciclo de respiración forzada del individuo. Además, se proporcionan las bases para generar un nuevo dispositivo que pueda emular el funcionamiento de este tipo de implantes y aumente la eficiencia del tratamiento de dicha patología.
In Mexico, the mortality rate due to bronchial respiratory sickness is placed in the sixth position, according to statistics from the National Institute of Breathing Sickness (INER), so it is convenient to increment the efficiency of treatments for those pathologies. The intrabronchial valve is a recommended alternative method; being it main objective to avoid invasive surgery and increase the time and quality of patient´s life. Within this work a biomechanical analysis of an IBV® valve is carried out. Regarding the numerical analysis, the dimensions and mechanical properties of the valve were proposed based on catalogues published by the manufacturer as more reliable information was not available in the open literature. As a result, a new model was developed in which both materials Nitinol® and Silastic® are considered as the main valve materials. The proposed working conditions assume that the valve is implanted in folded form at the bronchus and then anchored when it is unfolded. Finite Element Method (FEM) was used to simulate the proposed working conditions. Results obtained show the structural performance and the level of stress generated in the implant during the breathing cycle. In addition, it provides the knowledge to generate a new device that could emulate the performance of these implants and develop a more efficient treatment this disease.
Subject(s)
Lung Neoplasms/surgery , Lung Neoplasms/diagnosis , Lung Neoplasms/nursing , Lung Neoplasms/epidemiology , Lung Neoplasms/physiopathology , Lung Neoplasms/chemically induced , Lung Neoplasms/pathology , Lung Neoplasms/chemistry , Lung Neoplasms/drug therapy , Heart Valves/abnormalities , Heart Valves/physiology , Heart Valves/immunology , Heart Valves/pathology , Heart Valves/chemistryABSTRACT
OBJETIVO: Apresentar um método alternativo para detectar micrometástases em linfonodos previamente negativos para câncer de pulmão não-pequenas células (CPNPC) pela coloração de rotina com hematoxilina-eosina. MÉTODOS: Setenta e sete linfonodos hilares e mediastinais ressecados de 18 pacientes portadores de CPNPC foram investigados para a presença de micrometástases associando-se análise em microsséries e imunoistoquímica. RESULTADOS: Micrometástases foram detectadas após a identificação de células neoplásicas citoqueratina e cromogranina positivas em microsséries de linfonodos. Dos 18 pacientes inicialmente estadiados como pN0 pela coloração de rotina com hematoxilina-eosina, 9 (50 por cento) foram reestadiados como N1, e o prognóstico foi reavaliado em função de parâmetros histológicos e clínicos. A comparação das curvas de sobrevida mostrou que os pacientes sem micrometástases tiveram maior sobrevida do que os portadores de micrometástases. Além disso, após a análise multivariada controlada para idade, sexo, tipo histológico e reestadiamento, a presença de micrometástases mostrou-se como um fator independente na sobrevida. Entre os pacientes que haviam sido previamente estadiados como pN0, o risco de morte mostrou-se 7 vezes maior para os que foram posteriormente diagnosticados com micrometástases do que para aqueles nos quais não foram identificadas micrometástases. CONCLUSÃO: A combinação da análise em microsséries com a imunoistoquímica pode representar um método alternativo de baixo custo e menos demorado para identificar metástases ocultas e prever o prognóstico em pacientes portadores de CPNPC pN0 cujos tumores foram cirurgicamente ressecados. São necessários estudos prospectivos randomizados com casuísticas maiores para determinar a acurácia desse método alternativo.
OBJECTIVE: To present an alternative method of detecting micrometastases in lymph nodes previously testing negative for non-small cell lung cancer (NSCLC) by routine hematoxylin-eosin staining. METHODS: A total of 77 hilar and mediastinal lymph nodes resected from 18 patients with NSCLC were investigated for the presence of micrometastases using a combination of microarray analysis and immunohistochemistry. RESULTS: Micrometastases were detected by identifying cytokeratin- and chromogranin-positive cells in lymph node microarrays. Of the 18 patients initially staged as pN0 through routine hematoxylin-eosin staining, 9 (50 percent) were restaged as N1, and the prognoses were re-evaluated in terms of histological and clinical parameters. The comparison of the survival curves revealed that survival was higher in the patients without micrometastases than in those with micrometastases. In addition, in the multivariate analysis adjusted for age, gender, histological type, and restaging, the presence of micrometastases proved to be an independent predictor of survival. Among patients who had been previously staged as pN0, the risk of death was found to be 7-times greater for those later diagnosed with micrometastases than for those in whom no micrometastases were identified. CONCLUSION: The combination of microarray analysis and immunohistochemistry might represent a low-cost and less time-consuming alternative for identifying occult micrometastases and predicting prognoses in surgically resected patients with pN0 NSCLC. Larger randomized, prospective studies are needed in order to determine the accuracy of this method.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Carcinoma, Non-Small-Cell Lung/secondary , Chromogranin A/analysis , Keratins/analysis , Lung Neoplasms/pathology , Lymph Nodes/pathology , Brazil , Carcinoma, Non-Small-Cell Lung/chemistry , Follow-Up Studies , Immunohistochemistry , Lymph Node Excision , Lung Neoplasms/chemistry , Lymphatic Metastasis/pathology , Microarray Analysis , Neoplasm Staging/methods , Prognosis , Biomarkers, Tumor/analysisABSTRACT
El linfoma no Hodgkin anaplásico de células grandes, positivo al antígeno Ki-1, es una entidad bien reconocida. La característica clínica usual es la linfadenopatía con extensión mediastinal y en la enfermedad extranodal, que ocurre en la mitad de los casos, es la piel el sitio más común, con afección poco frecuente a médula ósea, pulmón y sistema nervioso. La mayor frecuencia de presentación del linfoma anaplásico de células grandes es en la población joven, con pronóstico más favora ble que en la población adulta. El linfoma anaplásico de células grandes primario de pulmón es una entidad clínica rara. Su comportamiento clínico corresponde a un linfoma de alto grado y en la mayoría de los casos se presentan al diagnóstico como una enfermedad en estadio avanzado. Se informa un caso pediátrico de linfoma anaplásico de células grandes primario de pulmón, ALK 1 positivo, que es un marcador pronóstico y específico de esta entidad.
Ki 1 anaplastic large cell non Hodgkin lymphoma is a well recognized clinical entity. The main clinical feature includes lymphadenopathy with mediastinal sparing. In the extranodal disease, which occurs in approximately half of the cases, the skin is the most common site; bone marrow, lung and central nervous system are generally not involved. Anaplastic large cell lymphoma is more common among young people, in whom the prognosis is more favorable. Primary anaplastic large cell lymphoma of the lung is a rare clinical entity. Its clinical expression is similar to a high grade malignant lymphoma, and in most cases the diagnosis is made in advanced stages. We present a pediatric case with ALK1 positive anaplastic large cell lymphoma of the lung.
Subject(s)
Child , Humans , Male , Lung Neoplasms/chemistry , Lymphoma, Large B-Cell, Diffuse/chemistry , Membrane Proteins/analysis , Activin Receptors, Type II , Lung Neoplasms/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosisABSTRACT
Mouse B16LuF1 melanoma cells of lower metastatic potential to lung were treated in vitro with same concentration (50 microM) of gangliosides isolated from B16LuF5, B16LuF9 or B16LuF10 cells with higher metastatic potential to lung (LuF1< LuF5< LuF9< LuF10) and injected to groups of normal mice through tail vein. The number of metastatic tumor nodules formed in lung increased in mice receiving B16LuF5, B16LuF9 and B16LuF10-ganglioside-treated B16LuF1 cells compared to mice receiving B16LuF1 cells without any ganglioside treatment. Metastatic potential of B16LuF1 cells gradually increased after treatment with gangliosides of B 16-melanoma cells of increasing metastatic potential to lung. The six major gangliosides isolated from B16LuF10 cells corresponded with standard gangliosides GT1b, GD1b, GD1a, GM1, GM2 and GM3 respectively on TLC-analysis. When B16LuF1 cells were treated in vitro with each of these six individual gangliosides and injected to groups of normal mice through tail vein the number of tumor nodules formed in lung varied. The four groups of mice receiving B16LuF1 cells treated with each of four gangliosides corresponding to GT1b, GD1b, GD1a or GM1 produced lung metastasis comparable to that of untreated control group. Only remaining two gangliosides which corresponded with standard gangliosides GM2 and GM3 increased metastatic potential of B16LuF1 cells. Thus, these results indicated that gangliosides GM2 and GM3 of B16-melanoma cells are definitely associated with metastatic potential of these tumor cells.
Subject(s)
Animals , Antigens, Tumor-Associated, Carbohydrate/isolation & purification , Gangliosides/isolation & purification , Lung/drug effects , Lung Neoplasms/chemistry , Melanoma, Experimental/chemistry , Mice , Mice, Inbred C57BL , Neoplasm Metastasis/pathology , Tumor Cells, CulturedABSTRACT
The identification of primary location of a metastatic tumor is a difficult diagnostic problem and sometimes can be facilitated by the use of immunohistochemical markers. Thyroid transcription factor-1 (TTF-1) is a 38-kDa nuclear homeodomain transcription factor that is expressed specifically in lung or thyroid neoplasms. Cytokeratin 20 (CK20) is a 46-kDa low-molecular-weight cytokeratin that shows restricted expression in adenocarcinomas of the gastrointestinal tract (GIT) and transitional cell carcinomas of the urinary tract. We studied the immunohistochemical expression of TTF-1 and CK20 in 68 metastatic carcinomas in cervical lymph nodes. The primary sites were the lung in 29 cases, stomach in 13, colorectum in 3, and other sites in 23. TTF-1 expression was detected in 69.0% of metastatic lung carcinomas and none in metastatic GIT carcinomas, whereas CK20 expression was detected in 68.8% of metastatic GIT carcinomas and none of metastatic lung carcinomas. TTF-1 had a specificity of 0.95 and a sensitivity of 0.69 for metastatic lung carcinoma, whereas CK20 had a specificity of 1.00 and a sensitivity of 0.69 for metastatic GIT carcinoma. These results indicate that TTF-1 and CK20 should be the first choice as a component of antibody panel to prove or to exclude the lung and GIT origin, respectively, especially in patients presenting with metastatic carcinomas of unknown primary site.
Subject(s)
Humans , Adenocarcinoma/chemistry , Carcinoma/chemistry , Gastrointestinal Neoplasms/chemistry , Homeodomain Proteins/analysis , Intermediate Filament Proteins/analysis , Keratin-20 , Lung Neoplasms/chemistry , Lymph Nodes/chemistry , Lymphatic Metastasis/diagnosis , Neck , Neoplasms, Unknown Primary/chemistry , Nuclear Proteins/analysis , Sensitivity and Specificity , Transcription Factors/analysis , Biomarkers, Tumor/analysisABSTRACT
BACKGROUND: CD44 is a cell surface adhesion molecule which has been implicated in various biologic functions as lymphocyte homing and activation, cellular migration and extracellular matrix adhesion. Over-expression of CD44v8- 10 has been found in several cancers and is considered to be associated with tumor progression and metastasis. Recently, a novel molecular method, CD44v8- 10/CD44v10 competitive reverse transcription-polymerase chain reaction(RT-PCR) has been developed for detecting cancer cells over-expressing CD44v8-10. METHODS: We analyzed from benign and malignant pleural effusion and ascites by CD44 competitive RT-PCR and compared to the conventional cytology. RESULTS: The CD44 competitive RT-PCR analysis showed that all the 24 samples associated with benign disease presented a predominant expression of the CD44v10 transcript (v8-10/v10 ratio: 0.126-0.948), whereas 6 of 7 malignant pleural samples associated with cytology positive cancer expressed the CD44v8-10 transcript (v8-10/v10 ratio > 1.00). CONCLUSION: These results indicate that CD44 competitive RT-PCR assay is a useful and adjunct to cytological examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusion.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Hyaluronan Receptors/analysis , Ascites/pathology , Ascites/immunology , Base Sequence , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/immunology , Comparative Study , Gastrointestinal Neoplasms/pathology , Gastrointestinal Neoplasms/immunology , Lung Neoplasms/pathology , Lung Neoplasms/chemistry , Middle Aged , Molecular Sequence Data , Pleural Effusion, Malignant/pathology , Pleural Effusion, Malignant/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and SpecificityABSTRACT
The purpose of this study is to evaluate the clinical significance of E-cadherin expression in lung cancer. E-cadherin expression was detected by immunohistochemistry using a monoclonal antibody (HECD-1). Strongly positive (++) E-cadherin tumors were classified as a type of preserved E-cadherin expression (Pr type), while the others (+, - tumors) were classified as a type of reduced E-cadherin expression (Rd type). The frequency of Pr type in squamous cell carcinomas (59.0%) was higher than Rd type. However, in adenocarcinomas, the frequency of Rd type was higher than Pr type. E-cadherin expression pattern was significantly correlated with differentiated state (Pearson correlation coefficient 0.394, p>0.001). E-cadherin expression of well-differentiated tumors was more frequently preserved than that of poorly differentiated tumors (60.0% vs. 25.9%). With regard to the correlation between E-cadherin expression and stages of lymph node metastasis in non-small cell lung cancers, the percentage of tumors with Pr type E-cadherin expression declined from 66.3% (> or = N1) to 38.6% (> or = N2), indicating that loss of E-cadherin expression is responsible for acquisition of invasive potential of lung cancer as well as the possible role of E-cadherin in the histological differentiation of lung cancer.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Antibodies, Monoclonal , Cadherins/immunology , Cadherins/biosynthesis , Cadherins/analysis , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/chemistry , Immunohistochemistry , Lung Neoplasms/pathology , Lung Neoplasms/metabolism , Lung Neoplasms/chemistry , Lymph Nodes/pathology , Middle Aged , Predictive Value of Tests , PrognosisABSTRACT
The biologic characteristics of the two human giant-cell lung carcinoma strains with high (strain D) and low metastatic potential (strain C) were studied, including karyotype of chromosome, intracellular free calcium ([Ca2+]i), morphologic changes of cell surface and the expression of nm23-H1, p53, ras, c-myc, c-erbB2, bcl-2 genes and PCNA. The correlation between different biologic features and the metastatic potential of the two strains was analyzed. We found: 1) Both strains had the karyotypic abnormality of -13, -14, -15, +20, +21 with seven same marker chromosomes. Only strain D had the karyotypic abnormality of +7, -17, -18, +X, 7p+; 2) [Ca2+]i of the strain C (984.7 +/- 573.8) and D (517.6 +/- 216.6) was significantly different (p < 0.05). The amplitude of intracellular calcium oscillations of strain C was lower than the one of strain D; 3) strain C had more villous-like protrusions on the cell surface, whereas strain D had more bubble-like protrusions; 4) The expression of nm23-H1 and p53 protein of strain C was all higher than that of strain D. The expression of PCNA of strain C was lower than strain D; 5) nm23-H1 mRNA levels of strain C was lower than that of strain D. We consider that the karyotype of chromosomes, intracellular free calcium, the structure of cell membrane and the expression of nm23-H1 gene, p53 gene, PCNA could be closely related to the metastatic potential of human giant-cell lung carcinoma. They could be used as the sign for judging whether the tumor will metastasize in clinical practice as well as in judging the prognoses of patients.
Subject(s)
Calcium/analysis , Carcinoma, Giant Cell/chemistry , Chromosome Aberrations , Chromosomes/genetics , Gene Expression , Genes, bcl-2/genetics , Genes, ras/genetics , Humans , Intracellular Fluid/chemistry , Karyotyping , Lung Neoplasms/chemistry , Monomeric GTP-Binding Proteins , NM23 Nucleoside Diphosphate Kinases , Neoplasm Metastasis/genetics , Nucleoside-Diphosphate Kinase , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/genetics , Tumor Suppressor Protein p53/geneticsABSTRACT
Cyclin D1, a G1 cyclin, has been implicated in the oncogenesis of various types of malignancies via deregulation of cell cycles. Amplification of cyclin D1 as a part of 11q13 amplicon has been reported in lung cancer as well as a subset of carcinomas arising from various organs including breast, head and neck, and esophagus. In addition to its role as an oncogene, several recent studies have suggested that amplification is indicative of poor prognosis. In this study we examined the cyclin D1 protein expression in 102 consecutive cases of lung cancers using the microwave enhanced immunohistochemical staining method and correlated the data with the histologic subtype and grade, Ki-67 (MIB-1) labeling index, and survival. Nuclear positive staining was observed in 18 cases (18 %) of lung cancers. Although squamous cell carcinoma demonstrated a higher rate of expression (12 /58, 21%), three of 33 adenocarcinomas (9%) revealed overexpression and both adenocarcinoma and squamous cell carcinoma components within the adenosquamous carcinoma showed nuclear staining. There was no correlation between cyclin D1 overexpression and histologic grade, Ki-67 (MIB-1) labeling index, and survival. These observations indicate that cyclin D1 protein overexpression might be implicated in the oncogenesis of the various histologic types of non-small cell lung carcinomas but it has no usefulness as a prognostic marker.
Subject(s)
Humans , Cyclin D1 , Cyclins/analysis , Immunohistochemistry , Lung Neoplasms/chemistry , Neoplasm Staging , Oncogene Proteins/analysisSubject(s)
Humans , Drug Resistance/physiology , Genes, Tumor Suppressor/genetics , Lung Neoplasms/genetics , Molecular Biology , Oncogenes/physiology , Carcinoma, Non-Small-Cell Lung/therapy , Drug Resistance/genetics , Genes, Tumor Suppressor/physiology , Lung Neoplasms/chemistry , Lung Neoplasms/pathology , Neoplasm Staging/mortality , Oncogenes/genetics , Prognosis , Oncogene Proteins v-fos/adverse effectsABSTRACT
Normal bronchopulmonary tissues and pulmonary carcinomas including three major types (squamous cell carcinoma, adenocarcinoma, and small-cell carcinoma) were studied using three biotinylated lectins (Bauhinia purpurea [BPA], Phaseolus vulgaris [PHA], and Maclura pomifera [MPA]) by avidin biotin peroxidase complex (ABC) method. The study demonstrated that BPA binds with macrophages and pneumocytes of normal tissue, and with adenocarcinoma and small-cell carcinoma, but nonreactive with squamous cell carcinoma. PHA and MPA bound to all the normal components of bronchopulmonary tree and carcinomas of all types. Adenocarcinoma showed the highest density of reacting sites for BPA and MPA, and squamous cell carcinoma showed the highest binding sites for PHA, while small-cell carcinoma were the lowest reacting variant for all lectins. Lectins used in this study have limited usefulness for the diagnosis of pulmonary neoplasms.